19 March 2019 Submission
Consumers Health Forum

Read the submission 

We are pleased to provide a submission supporting the continuation and strengthening of the Tobacco Control Regulations in Australia. Since the introduction of the Tobacco Control Regulations in the early 1990s, Australia has taken significant steps to reduce smoking and minimise the long-term health risks associated with tobacco. Prevention and cessation of smoking has been a remarkable public health achievement in Australia, which CHF believes is attributed to the regulatory and population based approach of the Tobacco Control Regulations. Despite the progress that has been made, 1 in 8 Australians still smoke daily, over 15,000 Australians die from tobacco-related causes each year, and an estimated 20% of the nation’s cancer deaths each year is caused by smoking. At a minimum, we recommend maintaining current regulations such as mandatory health warnings and would strongly encourage renewed efforts to stop and reduce tobacco smoking and for this review to ensure regulations and compliance processes are future-proofed.

8 March 2019 Submission
Consumers Health Forum

CHF response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2

CHF supports the changes that the GPPCCC have been made in their Phase 2 Report and feel that their vision of the health system aligns closely with what we hear from members. We are pleased that our earlier comments have been taken on board but would like to see more detail around patient activation and the role of consumer leadership in the proposed changes to the MBS items. We believe that this element is essential to successful patient and family-centred primary health care in Australia. Beyond the scope of this Committee’s work, we would like to highlight the importance of strong change management to ensure recommendations align with consumer and sector expectations in the design, implementation and evaluation stages.

Read the CHF response to the Report from the General Practice and Primary Care Clinical Committee: Phase 2

CHF Response to the MBS Review Taskforce Diagnostic Medicine Clinical Committee  

CHF supports the DMCC’s recommendations in principle in order to reduce inappropriate requesting of pathology and Diagnostic Imaging tests. In particular, we feel that Clinical Decision Support is a platform to make quality a focus of requests and an opportunity for consumer education (informed clinical and financial consent). Beyond the scope of the DMCC’s work, we urge the government to implement Clinical Decision Supports quickly and consider the additional support and funding that will help the success of this process.

Read the CHF Response to the MBS Review Taskforce Diagnostic Medicine Clinical Committee  

8 March 2019 Submission
Consumers Health Forum

CHF appreciates the opportunity to provide a comment to the Therapeutic Goods Administration (TGA) proposal to introduce a Unique Device Identification (UDI) system for medical devices in Australia.

At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation questions have been formed with a patient-centred approach in mind.

Read the Submission here

5 March 2019 Submission
Consumers Health Forum

The CHF supports the reintroduction of pills into the scope of the remade Order. The omission of these from the current Order is an unfortunate regulatory oversight. Consumers implicitly trust the regulatory system to ensure any product made available to them undergoes rigorous assessment of quality, safety and efficacy. Currently that trust is being abused.

Read the submission here

5 March 2019 Submission
Consumers Health Forum

We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming available to consumers, decreasing the risk to consumer health of the devices not functioning as intended.

The CHF acknowledges that there is potential for a delay in accessibility for critical medical devices should certain devices be reclassified into a higher Class. However we believe that it is crucial that any such critical devices be rigorously assessed for safety, efficacy and quality before being made available to ensure faulty or ineffective devices are not given to consumers. Additionally we believe the proposed transitional arrangements should give manufacturers and sponsors sufficient time to ensure their devices are assessed appropriately and are able to be made available to consumers when the new classification applies.

Read the submission here

 

5 March 2019 Submission
Consumers Health Forum

At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind.
CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not changes to those regulatory requirements. However, as other consultations are currently open to change regulations for Software as a Medical Device (SaMD) it would be remiss for CHF to not include some forward-looking advice on out of scope but related matters.

Read the submission here 

4 March 2019 Submission
Consumers Health Forum

CHF appreciates the opportunity to provide a comment in response to proposed changes to a number of definitions and the scope of the medical device regulatory framework in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation questions have been formed with a patient-centred approach in mind.

Read the submission here

4 March 2019 Consumers Shaping Health
Consumers Health Forum
27 February 2019 Presentations and Speeches
Consumers Health Forum

During 2019, the Therapeutic Goods Administration (TGA) will continue to implement changes in response to the Review of Medicines and Medical Devices Regulation (MMDR). This webinar aimed to update consumers on these medical device consultations and answer questions from consumers. 

Watch the webinar

Download the presentation

12 February 2019 Consumers Shaping Health
Consumers Shaping Health

Pages